| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | 0 | 603.924 | 1.906.438 | 1.590.641 | 1.481.899 | 1.600.597 | 1.966.667 | 2.633.700 |
| Total Income - EUR | - | - | 0 | 603.960 | 1.906.478 | 1.591.891 | 1.483.560 | 1.611.909 | 1.967.552 | 2.640.731 |
| Total Expenses - EUR | - | - | 7.696 | 610.192 | 1.869.110 | 1.546.640 | 1.453.516 | 1.615.610 | 1.956.470 | 2.617.549 |
| Gross Profit/Loss - EUR | - | - | -7.696 | -6.233 | 37.368 | 45.251 | 30.044 | -3.701 | 11.083 | 23.182 |
| Net Profit/Loss - EUR | - | - | -7.696 | -7.105 | 32.086 | 39.125 | 25.872 | -3.742 | 9.130 | 20.134 |
| Employees | - | - | 1 | 3 | 3 | 2 | 3 | 3 | 5 | 6 |
Check the financial reports for the company - Quick Pharma Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | 7 | 0 | 0 | 7.882 | 7.078 | 2.976 | 1.282 | 802 |
| Current Assets | - | - | 876 | 257.824 | 529.099 | 545.855 | 573.625 | 628.580 | 1.001.868 | 1.141.329 |
| Inventories | - | - | 0 | 108.819 | 204.561 | 255.689 | 286.383 | 303.502 | 256.309 | 218.579 |
| Receivables | - | - | 649 | 123.381 | 298.058 | 256.317 | 243.279 | 307.103 | 666.331 | 846.954 |
| Cash | - | - | 227 | 25.625 | 26.480 | 33.849 | 43.963 | 17.975 | 79.229 | 75.795 |
| Shareholders Funds | - | - | -7.600 | -4.895 | 27.286 | 65.894 | 90.305 | 86.843 | 93.437 | 113.048 |
| Social Capital | - | - | 96 | 9.765 | 9.576 | 9.394 | 9.186 | 9.214 | 9.186 | 9.135 |
| Debts | - | - | 8.483 | 263.294 | 502.062 | 487.874 | 490.440 | 544.744 | 909.743 | 1.029.082 |
| Income in Advance | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Quick Pharma Srl